The Invacare[®] XPO, Portable Oxygen Concentrator

• Truly portable

Ideal for active and travelling oxygen-dependent patients

Maximum independence

Compact and lightweight, encourages ambulatory patients to make the most of their independent lifestyle

Clinical efficient oxygen delivery

Sensi-Pulse constant minute-volume technology delivers only clinical beneficial oxygen at the beginning of inspiration, with comfortable bolus delivery and ensuring patients stay oxygenated

• The perfect ambulatory partner

True portability, high clinical efficacy and a simple user interface gives patients confidence and freedom to travel, with the economic benefits of the non-delivery model

Proven track record

4-years proven track record with more than 50'000 patients treated worldwide

Don't wait any longer, offer your oxygen-dependent patients a more active and independent lifestyle!

invacare.eu.com

European Headquarter: Invacare International Sàrl, Route de Cité-Ouest 2, CH-1196 Gland Tel: (41) (0)22 354 60 10 hgeurope@invacare.com www.invacare.eu.com

Sales Units: Belgium & Luxemburg: Invacare nv, Autobaan 22, B-8210 Loppern Tel: (32) (0)50 83 10 10 belgium@invacare.com www.invacare.be

Denmark: Invacare A/S, Sdr. Ringvej 37, DK-2605 Invacare Poirier SAS, Route de St Brøndby Tel: (45) (0)36 90 00 00 denmark@invacare.com www.invacare.dk

Deutschland: Invacare GmbH, Alemannenstraße 10, Invacare Ireland Ltd, Unit 5 Seatown D-88316 lsny Tel: (49) (0)75 62 7 00 0 kontakt@invacare.com / www.invacare.de

Ulrich Alber GmbH. Vor dem Weissen Stein 21, D-72461 Albstadt-Tailfingen Tel: (49) (0)7432 2006 0 info@ulrich-alber de

European Distributor Organisation: Invacare, Kleiststraße 49, D-32457 Porta Westfalica Tel: (49) (0)57 31 754 540 edo@invacare.com / www.invacare.eu.com

España: Invacare SA, c/Areny s/n, Polígon Industrial de Celrà, E-17460 Celrà (Girona) Tel: (34) (0)972 49 32 00 contactsp@invacare.com www.invacare.es

France: Boch E-37230 Fondettes Tel: (33) (0)2 47 62 64 66 contactfr@invacare.com www.invacare.fr

Ireland: Business Campus, Seatown Road, Swords, County Dublin - Ireland Tel: (353) 1 810 7084 ireland@invacare.com / www.invacare.ie

Italia:

Invacare Mecc San s.r.l., Via dei Pini 62, I-36016 Thiene (VI) Tel: (39) 0445 38 00 59 italia@invacare.com www.invacare.it

Nederland: Invacare BV, Celsiusstraat 46, NL-6716 BZ Ede Tel: (31) (0)318 695 757 nederland@invacare.com /

www.invacare.nl

csede@invacare.com Invacare AS, Grensesvingen 9. Postboks 6230, Etterstad, N-0603 Oslo Tel: (47) (0)22 57 95 00 norway@invacare.com www.invacare.no island@invacare.com

Österreich: Invacare Austria GmbH, Herzog Odilostrasse 101 A-5310 Mondsee Tel: (43) 6232 5535 0 info-austria@invacare.com / www. invacare.at

Portugal Invacare Lda, Rua Estrada Velha, 949, P-4465-784 Leça do Balio Tel: (351) (0)225 1059 46/47 portugal@invacare.com www.invacare.pt



Sverige & Suomi:

Tel: (46) (0)8 761 70 90

sweden@invacare.com

www.invacare.se

Switzerland

finland@invacare.com

CH-4108 Witterswil

www.invacare.ch

United Kingdom

Customer services

UK@invacare.com

www.invacare.co.uk

Tel: (44) (0)1656 776222

Tel: (41) (0)61 487 70 80

switzerland@invacare.com

Spånga

Invacare AB, Fagerstagatan 9, S-163 91

Invacare AG. Benkenstrasse 260.

Invacare Limited, Pencoed Technology

Park, Pencoed, Bridgend CF35 5AQ Switchboard Tel: (44) (0)1656 776200

ASPH¹LTE 334 860 285 R.C.S. TOURS

Yes, you can.

Clinical Evidence on XPO₂ Portable Oxygen Concentrator

COUILLARD A, FORET D, BAREL P, BAJON D oxygen therapy by a portable concentrator Rev mal respir. 2010 NOV; 27(9):1030-8.



Authors: Couillard A, Foret D, Barel P, Bajon D

Title: Oxygen therapy by a portable concentrator with a demand valve: a randomised controlled study of its effectiveness in patients with COPD

Source: Rev Mal Respir. 2010 Nov;27(9):1030-8.

Study Aim and design

- This prospective randomized study aimed to compare clinical efficacy of XPO_2 pulse-dose portable concentrator (O_2 -P) with traditional continuous-flow liquid oxygen (O_2 -L)
- Nineteen (19) patients with stable, uncomplicated oxygen-dependent COPD were randomly assigned on pulse-dose portable concentrator (O_2-P) or continuous-flow liquid oxygen (O_2-L)
- All patients were existing home oxygen users with an O_2 prescription at rest or deambulation, and had the ability to carry portable devices
- Patients were assessed for exercise capacity, dyspnea and SaO₂ at rest and during exercise
- A standard 6-minute walk test (6MWT) was used, and each patient underwent one of the two with the selected delivery system. After 1 hour rest, the 6MWT was repeated with the other oxygen device

Key findings

• This non-inferiority clinical trial on nineteen (19) patients demonstrated that the clinical benefits of pulse-dose portable concentrator (O_2 -P) are similar to traditional continuous-flow liquid oxygen (O_2 -L)

• The portable oxygen concentrator (O_2-P) allowed sustained mobility and ambulation without increased dyspnea compared to O_2-L , with the independence of not relying on oxygen delivery

- The decrease in SaO₂ during the 6MWT were identical for O₂-P and O₂-L , as demonstrated in previously published clinical literature
- There was no statistically significant difference between SaO₂ at rest and after the 6MWT obtained while using O₂-P and O₂-L
- Exercise capacity, dyspnea and SaO_2 at rest and during exercise in patients using this pulse-dose portable concentrator were similar to those using continuous-flow portable liquid oxygen device

Key quotes

- "This study demonstrates that clinical efficacy of a pulse-dose portable concentrator (O_2 -P) is identical to continuous-flow portable liquid oxygen device (O_2 -L)"
- "Improvements in patients independence with XPO₂ pulse-dose portable concentrator are similar to those observed with continuous-flow portable liquid oxygen device, and could reduce the cost of oxygen therapy"
- "When patients carried the device on the shoulder, the portable oxygen concentrators was considered lighter and more practical, especially when compared with a fully loaded O_{2} -L device"

Key illustrations



Figure 1 There was no statistically significant difference between exercise capacity of the O₂-P and the O₂-L group



Figure 2 The SaO₂ during the 6-minutes walking test was very similar in the O₂-P and O₂-L group

CLINICAL EVIDENCE ON XPO, PORTABLE OXYGEN CONCENTRATOR